evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,805 questions · 2,912 findings · 307 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 706 · 24.2%GRADE not reported 133 · 4.6%Very low 786 · 27%Low 696 · 23.9%Moderate 474 · 16.3%High 117 · 4%

Vigabatrin vs placebo

50% or greater reduction in seizure frequency · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).

1 finding from 1 review

Combined trabeculotomy with trabeculectomy vs trabeculotomy

Proportion of participants with IOP≤ 21 mmHg, with or without ocular hypotensive medications 1 year · children at or before five years of age with primary congenital glaucoma

It is very uncertain whether combined trabeculotomy with trabeculectomy changes surgical success: proportion with postoperative IOP ≤ 21 mmHg with… compared with trabeculotomy (very low certainty).

1 finding from 1 review

Viscotrabeculotomy vs conventional trabeculotomy

Proportion with postoperative IOP ≤ 21 mmHg (surgical success) with or without glaucoma medications 6 months after surgery · children at or before five years of age with primary congenital glaucoma

It is very uncertain whether viscotrabeculotomy changes proportion with postoperative IOP ≤ 21 mmHg (surgical success) with… compared with conventional trabeculotomy (very low certainty).

1 finding from 1 review